The first 1 billion varieties were born! 31 billion products of 100 billion pharmaceutical giants and 8 first applications for consistency evaluation

In recent days, Shanghai Pharmaceutical announced its 2018 performance, achieving revenue of 159084 million yuan, a year-on-year increase of 21.58%; net profit of 3.881 billion yuan, a year-on-year increase of 10.24% Among them, the pharmaceutical industry revenue was 19.462 billion yuan, an increase of 29.86% year on year; the pharmaceutical business revenue was 139.622 billion yuan, an increase of 20.51% year on year The net profit was 3.881 billion yuan, an increase of 10.24% on a year-on-year basis; the profit from the main business of the pharmaceutical industry was 1.667 billion yuan, an increase of 15.59%; the profit from the main business of the pharmaceutical industry was 1.756 billion yuan, an increase of 8.93% on a year-on-year basis; the profit from the participating enterprises was 648 million yuan, an increase of 17.38% on a year-on-year basis Main business (unit: 100 million yuan) pharmaceutical industry: 31 over 100 million products, the first 1 billion single product was born in Shanghai pharmaceutical products mainly focus on five treatment fields: digestive system and metabolism, cardiovascular, systemic anti infection, mental nerve and anti-tumor, producing nearly 700 drug varieties and more than 20 dosage forms In 2018, the pharmaceutical industry achieved sales revenue of 19.462 billion yuan, a year-on-year increase of 29.86%, and a gross profit margin of 57.63% The sales revenue of 60 key products increased by 28.52% year-on-year; the number of over 100 million products reached 31, an increase of 3 compared with that in 2017; the first occurrence of 1 billion varieties - tanshinone IIA Shanghai Pharmaceutical completed the acquisition of 26.34% equity of Guangdong techpool, realized absolute holding, and promoted the strategic transformation to the field of biomedical innovation Two core products, ulinastatin for injection (tianpuluoan) and urinary kallikrein for injection (kailikang), have filled in the gaps of the company's product line in the field of urinary protein The company has handed over the world's first and China's only oncolytic virus, ankeri (recombinant human type 5 adenovirus), to Guangdong Tianpu to start the re listing plan and expand the tumor market segment The company will continue to enrich its product lines through M & A and project introduction, continue to inject new energy into the development of Guangdong techpool, and build Guangdong techpool into a "leader in biomedicine worthy of respect and cooperation in critical areas" Pharmaceutical distribution: with an income of nearly 140 billion yuan, it has obtained 15 national general agents for pharmaceutical distribution of imported drugs The distribution network covers 31 provinces, municipalities and autonomous regions in China, including 24 provinces, municipalities and autonomous regions directly covered by holding subsidiaries In addition, there are many kinds of distribution, covering more than 20000 medical institutions In 2018, the sales revenue of pharmaceutical distribution business reached 139 billion 445 million yuan, with a year-on-year growth of 20.06% and a gross profit margin of 6.85% In February 2018, Shanghai Pharmaceutical completed the acquisition of kantle China, which improved the overall competitive pattern and industrial advantage of the distribution business Kantle achieved a net profit of 181 million yuan, an increase of 15% year on year After integrating kantle, Shanghai Pharmaceutical has become China's largest import general agent and distributor, signing strategic cooperation agreements with global famous pharmaceutical enterprises such as Roche, MSD, Gilead science, GlaxoSmithKline, Bayer, etc., and introducing heavy new drugs Among the new drugs approved for listing by CDE in 2018, there are 20 varieties imported through national commercial distribution companies Shanghai Pharmaceutical has obtained 15 national general agents of imported drugs, including two PD-1 new drugs, opdivo, keytruda, Japan's first-line liver cancer treatment new drugs, such as lovima (lovatinib mesylate capsule), and imported drugs in 2018 Products account for more than 55% of the company's drug distribution revenue It is worth mentioning that in the high-volume procurement, SHP has obtained 63% market share in the announced selection of the winning drug distributors in Shanghai, consolidating the leading advantages of Shanghai Pharmaceutical retail: in terms of online and offline integrated pharmaceutical retail business, there are more than 2000 retail pharmacies distributed in 16 provinces, regions and cities across the country Shanghai Huashi pharmacy is one of the pharmaceutical retail companies with the largest number of pharmacies in East China Shanghai Pharmaceutical cloud health is committed to creating an innovative pharmaceutical e-commerce model based on electronic prescription circulation In 2018, the pharmaceutical retail business realized sales revenue of 7.202 billion yuan, a year-on-year increase of 27.70%; the gross profit margin was 14.84% Yao Yun health aims at "Internet plus the leader and innovator of new retail of prescription drugs", taking "benefit medicine" as the series brand, from prescription acquisition and management, prescription payment and reasonable control, prescription realization and drug delivery, patient value-added service and other aspects of prescription circulation By the end of 2018, 8.4887 million e-prescriptions had been circulated nationwide, 340 medical institutions had been connected, and more than 3.6 million patients had been served R & D investment is nearly 1.4 billion: 7 new drug R & D projects, 8 consistency evaluation first applied for R & D investment of Shanghai Pharmaceutical mainly covering chemical drugs, traditional Chinese medicine and biological products, including innovative drugs, generic drugs and secondary development of listed varieties In 2018, R & D investment was nearly 1.4 billion yuan, and R & D expense investment totaled 1.061 billion yuan, a year-on-year increase of 34.22%, accounting for 5.45% of industrial sales revenue Among them, 18.70% went to the research and development of innovative drugs, 19.93% to the research and development of generic drugs, 33.60% to the secondary development of existing products and 27.77% to the consistency evaluation According to the data of new drug R & D project (unit: 10000 yuan), the sph3127 tablets of Shanghai Pharmaceutical officially entered into clinical phase II, and signed an agreement with Mitsubishi taganabe, Japan, to obtain the development and sales rights of the drug in major pharmaceutical market countries including the United States In addition, the company has launched the secondary development of varieties to make the old varieties glow with new vitality and promote the development of stock market through the active coordination of R & D and marketing Among them, Yangxin tablets continued to carry out a number of clinical studies, with sales revenue of nearly 200 million yuan; hongyuanda polysaccharide iron complex ranked first in the market share in the field of oral iron Major drug consistency evaluation project (unit: 10000 yuan) In terms of consistency evaluation, four varieties of captopril tablets, fluoxetine hydrochloride capsules metformin hydrochloride sustained release tablets and hydrochlorothiazide tablets of Shanghai Pharmaceutical have been approved, 32 product specifications have been completed and reported to the State Food and drug administration, nifedipine sustained release tablets, levonorgestrel tablets, compound reserpine tablets, aripiprazole tablets, duloxetine hydrochloride enteric coated capsules, bromopyridazine tablets, phosphoric acid Chloroquine tablets and primaquine phosphate tablets are the first to declare For future development, Zhou Jun, chairman of the board of directors, said that a new round of three-year plan will be launched in 2019, adhering to the four strategic measures of intensification, innovation, internationalization and integration of Finance and industry, and striving to build a Chinese pharmaceutical industry group with international competitiveness The pharmaceutical industry is transforming into high-end generic drugs and innovative drugs; the pharmaceutical business remains among the top three in China, transforming into a modern health service provider driven by service and technology Source: announcement of listed companies